Elbrus Capital Fund III has acquired a large minority stake in Breffi, a Russian omnichannel marketing company for pharmaceutical brands. The transaction amount was RUB 750 million. Most of the funds will be directed to the development of the company, the scaling of the current business and the creation of new digital products in the field of healthcare.
Since the founding of Breffi, the main focus of the company has been the promotion of branded medicines in Russia, mainly through the medical community. Currently, Breffi has over 100 clients, most of which are international pharmaceutical companies with a presence in Russia. Breffi’s revenue in 2021 is over RUB 500 million.
A key driver of Breffi’s development is the promotion of pharmaceutical brands through remote and digital channels. The company uses approaches based on dynamic data analysis, automation of communication processes with the target audience and the use of its own IT platforms. Breffi offers the pharmaceutical market new, digital promotion methods. A feature of Breffi’s offer for its customers is the guarantee of a return on their investment in brand promotion.
This is Breffi’s first experience in raising outside equity capital. The investments received from the Elbrus Capital fund will be directed to further business development. The company plans to scale up successfully operating services, enter promising related areas and strengthen the development of IT products. The parties did not disclose the assessment of the company. The founders of the company – Evgeny Gordeev, Irina Shramova and Anton Bondarenkowill continue to run the business while maintaining control over decision making.
Evgeny Gordeev said: “This investment for Breffi is, first of all, an opportunity to be more competitive in the fight for the best market experts. We will be able to realize what we have long dreamed of – to significantly enhance the development of our employees, to have more opportunities for high-quality implementation of projects, for experiments and creativity. The partnership with the Elbrus Capital Foundation is the first stage of our five-year development strategy, as a result of which we will help millions of patients to have a better quality of life. “
“Breffi’s services are becoming increasingly relevant as the digitalization of the pharmaceutical industry continues and as contacts with doctors shift from traditional appointments with medical representatives to digital channels. We hope that with the support of the Elbrus Capital fund, the company will be able to further strengthen its position in the omnichannel marketing market in the pharmaceutical sector, accelerate development and grow exponentially over the horizon of several years, ”said Alexander Savin, senior partner of Elbrus Capital funds.